Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2

$8m in cash
$20m facility extended to 2026...
• R327 shown to significantly reduce SARS-CoV-2 in hamsters
R327 SARS-CoV-2 Study Update – Efficacious Activity in Animal Models
The Company was pleased to release the findings of its SARS-CoV-2 studies. Undertaken by
an independent, third-party contract research organisation (CRO), Netherlands-based CRO,
Viroclinics, saw its SARS-CoV-2 studies demonstrate significant efficacious activity of R327
against the SARS-CoV-2 virus in the throat of Syrian golden hamsters – the gold-standard in
COVID studies.
Throughout the ongoing studies, R327 was shown to significantly reduce SARS-CoV-2 levels
in a dose-dependent manner, in throat swab samples collected from animals. The study
provided proof-of-concept that intra-nasal treatment with R327 has the potential to reduce
SARS-CoV-2 levels during infection.